openPR Logo
Press release

Thalassemia Treatment Market is driven by increase in number of altered thalassemia genes across the globe

09-17-2018 07:53 AM CET | Health & Medicine

Press release from: Transparency Market Research

Thalassemia Treatment Market is driven by increase in number

Thalassemia Treatment Market - Snapshot

The global thalassemia treatment market is driven by increase in number of altered thalassemia genes across the globe. The global market was valued at US$ 842.0 Mn in 2017 and is projected to expand at a CAGR of 7.9% from 2018 to 2026 to reach US$ 1,639.6 Mn by 2026. The global market is witnessing high growth owing to increase in blood transfusion and chelation therapy treatments, high number of bone marrow transplants, increase in number of spleen surgeries, and surge in R&D expenditure.

Thalassemia is a genetic blood disorder which produces abnormal hemoglobin in the body. This genetic blood disorder leads to the formation of a large number of red blood cells that are continuously destroyed, which further leads to anemia. The two types of proteins present in the blood of thalassemia patients are alpha globin and beta globin. Alpha thalassemia occurs primarily in people living in Southeast Asia, the Middle East, China, and Africa. Beta thalassemia occurs in people in the Mediterranean origin, and to a lesser extent in people in China, other Asians, and African Americans.

Obtain Report Details @ https://www.transparencymarketresearch.com/thalassemia-treatment-market.html

Chelation therapy and blood transfusion are the most common treatments for thalassemia patients, as these are cost effective and are easily available compared to bone marrow transplantation. Chelation therapy uses drugs such as deferasirox for the treatment of chronic iron overload occurs during multiple blood transfusions among non-transfusion-dependent thalassemia patients. Chelation therapy drugs used subcutaneous or intravenous with slow infusion technique for purifying blood increase the possibility of curing thalassemia patients.

Blood transfusion helps patients suffering from alpha thalassemia or beta thalassemia. The transfusion treatment procedure improves overall operational efficiency. High prevalence and incidence rates of thalassemia and rise in number of stem cell transplantations among the global population have resulted in increase in patient flow to private clinics and hospitals. These factors are projected to drive demand for blood transfusion procedure for thalassemia treatment in the near future. Moreover, advancements in gene therapy such as gene editing, stem cell therapy, and proliferation of new drugs for thalassemia treatment are anticipated to fuel the growth of the global thalassemia treatment market from 2018 to 2026.

The global thalassemia treatment market has been segmented based on treatment type and region. In terms of treatment type, the global market has been categorized into blood transfusion, chelating therapy, bone marrow transplant, and others. The chelation therapy segment accounted for major share of the global market in terms of revenue in 2017. The segment is projected to expand at an exponential growth rate during the forecast period. Blood transfusion offers several advantages over bone marrow transplantation such as low cost of treatment. Hence, blood transfusion is gaining popularity among thalassemia patients.

Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=44462

Geographically, the global thalassemia treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to lose market share between 2018 and 2026. The market in North America is primarily driven by rapidly increasing immigrant population from tropical regions, growing number of population with thalassemia carrier gene, and rise in birth rates due to variation of genes among the population in the U.S. Moreover, increase in same community marriage practices and high birth rate of alpha thalassemia patients have been observed in Asia Pacific.

This is projected to increase adoption of blood transfusion and chelation therapy treatments during the forecast period. Middle East & Africa is projected to be the fastest growing market for thalassemia treatment during the forecast period. Rest of Middle East & Africa dominated the thalassemia treatment market in the region, while the market in GCC Countries is estimated to expand at an exponential CAGR during the forecast period.

Companies such as bluebird bio, Inc., Acceleron Pharma, Inc., Novartis AG, Celgene Corporation, and Shire plc (Takeda Pharmaceuticals) accounted for the major share of the global thalassemia treatment market in 2016. Celgene Corporation has provided over 525,000 patients with the prescribed Luspatercept medicine. In 2017, the company accelerated 160 trials in approximately 60 indications and more than 25 new molecules have entered preclinical or phase 1 development.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=44462

Other global players operating in the market include Incyte Corporation, Kiadis Pharma, Gamida Cell, and Bellicum Pharmaceuticals. Companies are adopting the strategy of acquisition and collaboration with parallel companies to improve and strengthen geographic presence in the international market. Moreover, the partnership agreement with companies is expected to increase in number of clinical trials for thalassemia in the near future.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Thalassemia Treatment Market is driven by increase in number of altered thalassemia genes across the globe here

News-ID: 1241013 • Views:

More Releases from Transparency Market Research

Continuous Monitoring Products in Healthcare Industry Market to Surpass US$ 20.5 Bn by 2035 Driven by Regulatory Compliance and Remote Monitoring Demand
Continuous Monitoring Products in Healthcare Industry Market to Surpass US$ 20.5 …
The global Continuous Monitoring Products in Healthcare Industry market was valued at US$ 4.3 Bn in 2024 and is projected to reach more than US$ 20.5 Bn by 2035, expanding at a CAGR of 15.2% during the forecast period from 2025 to 2035, according to the latest research study by Transparency Market Research Inc. Stringent regulatory guidelines, increasing demand for patient safety, and advancements in cloud-connected monitoring equipment are among the
Laryngeal Implants Market to Surpass US$ 221.9 Mn by 2035 Amid Surge in Voice Disorder Diagnoses and Technological Innovation
Laryngeal Implants Market to Surpass US$ 221.9 Mn by 2035 Amid Surge in Voice Di …
The global laryngeal implants market was valued at US$ 136.1 Mn in 2024 and is projected to reach US$ 221.9 Mn by 2035, expanding at a CAGR of 4.5% from 2025 to 2035, according to a recent study by Transparency Market Research Inc. The rising prevalence of voice disorders, especially among the aging population, and the development of advanced biocompatible materials and minimally invasive surgical techniques are expected to drive
Drug-Eluting Stents Market to Reach US$ 14.2 Bn by 2035, Driven by Technological Advancements and Cardiovascular Disease Burden
Drug-Eluting Stents Market to Reach US$ 14.2 Bn by 2035, Driven by Technological …
The global drug-eluting stents (DES) market was valued at US$ 7.7 Bn in 2024 and is projected to surpass US$ 14.2 Bn by 2035, expanding at a CAGR of 5.7% during the forecast period from 2025 to 2035, according to a new market report published by Transparency Market Research Inc. Increasing prevalence of cardiovascular diseases (CVDs), rising demand for minimally invasive cardiac procedures, and technological advancements in drug and stent
Tissue Sealants & Adhesives Market to Surpass USD 4.6 Bn by 2035 | Rising Demand for Bio-Adhesives & Advanced Wound Care Drives Global Growth
Tissue Sealants & Adhesives Market to Surpass USD 4.6 Bn by 2035 | Rising Demand …
The global Tissue Sealants & Adhesives Market, valued at US$ 2,302.9 Mn in 2024, is poised for substantial expansion, projected to reach over US$ 4,607.0 Mn by 2035, growing at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2035. Transparency Market Research's latest analysis reveals that increasing adoption of bio-adhesives, heightened awareness of advanced wound care solutions, and a shift toward minimally invasive surgical procedures are the

All 5 Releases


More Releases for Thalassemia

Thalassemia Market to Witness Growth Acceleration | SG Pharma Pvt. Lmt.
The Thalassemia Market Report is designed to incorporate both qualitative and quantitative aspects of the industry with respect to each region and country involved in the study. Furthermore, It studies the market essential sectors such as top participants, expansion strategies, business models, and other industry features to improve the current strategy of key players. Facts and data are presented in reports using diagrams, graphs, pie charts, and other pictorial representations.
Global Thalassemia Market Size – Forecast to 2026
The findings reviewed by GME stated that the Global Thalassemia Market will expand with a CAGR value of 10.2 percent from 2021 to 2026. Several drivers are likely to accelerate the thalassemia market further, including an increasing occurrence of thalassemia, growing public awareness, expanding expenditure in research & development, and the growing need for improved curative gene therapy. Browse 159 Market Data Tables and 119 Figures spread through 189 Pages and
Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)” report studies Thalassemia is a blood disorder that causes abnormal production of hemoglobin in an affected person. It is a genetic disorder inherited from parents. Hemoglobin carries oxygen in the blood and is produced by two proteins called alpha globin and beta globin.
Thalassemia - Pipeline Review, H2 2017
Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H2 2017, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape. Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow
Thalassemia - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Thalassemia - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H1 2017, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape. Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms
Global Thalassemia Market Report: 2016 Edition
Thalassemia is a hereditary blood disorder in which a person’s body makes an abnormal form of hemoglobin, which is the protein molecule in red blood cells (RBCs), which carries oxygen. The disorder results in unwarranted damage of red blood cells, which leads to anemia. Anemia is a condition in which the body doesn’t have adequate amount of normal and healthy red blood cells. There are majorly two types of thalassemia